## Cédric Logé

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/54451/publications.pdf

Version: 2024-02-01

38 papers

1,045 citations

18 h-index 414034 32 g-index

44 all docs

44 docs citations

times ranked

44

1618 citing authors

#	Article	IF	CITATIONS
1	New Quinoxaline Derivatives as Dual Pim-1/2 Kinase Inhibitors: Design, Synthesis and Biological Evaluation. Molecules, 2021, 26, 867.	1.7	10
2	Exosomes as New Biomarkers and Drug Delivery Tools for the Prevention and Treatment of Various Diseases: Current Perspectives. International Journal of Molecular Sciences, 2021, 22, 7763.	1.8	22
3	Dibenzofuran Derivatives Inspired from Cercosporamide as Dual Inhibitors of Pim and CLK1 Kinases. Molecules, 2021, 26, 6572.	1.7	3
4	New azole antifungals with a fused triazinone scaffold. European Journal of Medicinal Chemistry, 2020, 189, 112082.	2.6	20
5	4-cholesten-3-one decreases breast cancer cell viability and alters membrane raft-localized EGFR expression by reducing lipogenesis and enhancing LXR-dependent cholesterol transporters. Lipids in Health and Disease, 2019, 18, 168.	1.2	13
6	Structure-based design of novel quinoxaline-2-carboxylic acids and analogues as Pim-1 inhibitors. European Journal of Medicinal Chemistry, 2018, 154, 101-109.	2.6	26
7	The amino acid substitution N136Y in <i>Candida albicans</i> sterol 14alpha-demethylase is involved in fluconazole resistance. Medical Mycology, 2016, 54, 764-775.	0.3	13
8	Activation of EGFR by small compounds through coupling the generation of hydrogen peroxide to stable dimerization of Cu/Zn SOD1. Scientific Reports, 2016, 6, 21088.	1.6	14
9	Synthesis and molecular modelling studies of 8-arylpyrido[3′,2′:4,5]thieno[3,2-d]pyrimidin-4-amines as multitarget Ser/Thr kinases inhibitors. European Journal of Medicinal Chemistry, 2015, 92, 124-134.	2.6	41
10	Screening and discovery of nitro-benzoxadiazole compounds activating epidermal growth factor receptor (EGFR) in cancer cells. Scientific Reports, 2015, 4, 3977.	1.6	15
11	Anti-proliferative and Pro-apoptotic Effect of Dichloromethane Extract of Octopus vulgaris By-Products on Human Breast Cancer Cell Lines. Waste and Biomass Valorization, 2015, 6, 237-242.	1.8	5
12	Development of new highly potent imidazo[1,2-b]pyridazines targeting Toxoplasma gondii calcium-dependent protein kinase 1. European Journal of Medicinal Chemistry, 2015, 105, 80-105.	2.6	25
13	Synthesis of new pyridazino [4,5-b] indol-4-ones and pyridazin-3 (2H)-one analogs as DYRK1A inhibitors. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 5037-5040.	1.0	17
14	Discovery of (7-aryl-1,5-naphthyridin-2-yl)ureas as dual inhibitors of ERK2 and Aurora B kinases with antiproliferative activity against cancer cells. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 3748-3752.	1.0	6
15	Discovery of a Novel Broad-Spectrum Antifungal Agent Derived from Albaconazole. ACS Medicinal Chemistry Letters, 2013, 4, 288-292.	1.3	42
16	Novel synthesis of angular thiazolo[5,4-f] and [4,5-h]quinazolines, preparation of their linear thiazolo[4,5-g] and [5,4-g]quinazoline analogs. Tetrahedron, 2013, 69, 3182-3191.	1.0	21
17	Synthesis and biological evaluation of new 5-benzylated 4-oxo-3,4-dihydro-5H-pyridazino[4,5-b]indoles as PI3Kα inhibitors. European Journal of Medicinal Chemistry, 2012, 57, 225-233.	2.6	27
18	Study of N1-alkylation of indoles from the reaction of 2(or 3)-aminoindole-3-(or 2)carbonitriles with DMF-dialkylacetals. Organic and Biomolecular Chemistry, 2012, 10, 4916.	1.5	13

#	Article	IF	CITATIONS
19	Synthesis and <i>in vitro</i> antifungal evaluation of 2-(2,4-difluorophenyl)-1-[(1 <i>H</i> -1,2,4-triazol-1-yl)propan-2-ols. Journal of Enzyme Inhibition and Medicinal Chemistry, 2011, 26, 261-269.	2.5	15
20	Design, Synthesis, and inâ€vitro Antifungal Activity of 1â€{(4â€&ubstitutedâ€benzyl)methylamino]â€2â€(2,4â€difluorophenyl)â€3â€(1 <i>H</i> à€1,2,4â€triazolâ€1â€ChemMedChem, 2011, 6, 816-825.	yl)µp6opana	â <b>€2⁄</b> â€ols.
21	Design, Synthesis, and Biological Evaluation of 1â€{(Biarylmethyl)methylamino]â€2â€(2,4â€difluorophenyl)â€3â€(1 <i>H</i> à61,2,4â€triazolâ€1â€yl)propanâ€Antifungal Agents: New Insights into Structure–Activity Relationships. ChemMedChem, 2011, 6, 1806-1815.	2â€ols as 1.6	Potent 10
22	Screening for amino acid substitutions in the Candida albicans Erg11 protein of azole-susceptible and azole-resistant clinical isolates: new substitutions and a review of the literature. Diagnostic Microbiology and Infectious Disease, 2010, 66, 373-384.	0.8	235
23	A convenient synthesis of 5-arylamino-4H-pyran-4-ones using palladium-catalyzed amination. Tetrahedron Letters, 2009, 50, 5729-5732.	0.7	16
24	Synthesis and structure–activity relationships of 2-phenyl-1-[(pyridinyl- and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf Medicinal Chemistry Letters, 2009, 19, 301-304.	50 547 To 1.0	l (piperidinylı 42
25	Design of new antifungal agents: synthesis and evaluation of 1-[(1H-indol-5-ylmethyl)amino]-2-phenyl-3-(1H-1,2,4-triazol-1-yl)propan-2-ols. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 5833-5836.	1.0	22
26	Design, synthesis and evaluation of 3-(imidazol- 1-ylmethyl)indoles as antileishmanial agents. Part II. Journal of Enzyme Inhibition and Medicinal Chemistry, 2009, 24, 1067-1075.	2.5	14
27	Novel 9-oxo-thiazolo[5,4-f]quinazoline-2-carbonitrile derivatives as dual cyclin-dependent kinase 1 (CDK1)/glycogen synthase kinase-3 (GSK-3) inhibitors: Synthesis, biological evaluation and molecular modeling studies. European Journal of Medicinal Chemistry, 2008, 43, 1469-1477.	2.6	55
28	Homology modeling of MT1 and MT2 receptors. European Journal of Medicinal Chemistry, 2008, 43, 1926-1944.	2.6	23
29	Synthesis of 3,5-bis(2-indolyl)pyridine and 3-[(2-indolyl)-5-phenyl]pyridine derivatives as CDK inhibitors and cytotoxic agents. Bioorganic and Medicinal Chemistry, 2008, 16, 4932-4953.	1.4	54
30	Design, synthesis, and evaluation of 1-(N-benzylamino)-2-phenyl-3-(1H-1,2,4-triazol-1-yl)propan-2-ols as antifungal agents. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1820-1824.	1.0	32
31	Design, synthesis and evaluation of new 6-substituted-5-benzyloxy-4-oxo- <i>4H</i> -pyran-2-carboxamides as potential Src inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2008, 23, 629-640.	2.5	6
32	Thiazolo[5,4-f]quinazolin-9-ones, inhibitors of glycogen synthase kinase-3. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 3419-3423.	1.0	57
33	Three-dimensional model of cytochrome P450 human aromatase. Journal of Enzyme Inhibition and Medicinal Chemistry, 2005, 20, 581-585.	2.5	16
34	Potent and Selective Farnesyl Transferase Inhibitors. Journal of Medicinal Chemistry, 2004, 47, 6812-6820.	2.9	22
35	Docking Study of Ligands into the Colchicine Binding Site of Tubulin. Journal of Enzyme Inhibition and Medicinal Chemistry, 2004, 19, 541-547.	2.5	36
36	Synthesis and Pharmacological Study of Rho-Kinase Inhibitors: Pharmacomodulations on the Lead Compound Fasudil. Journal of Enzyme Inhibition and Medicinal Chemistry, 2003, 18, 127-138.	2.5	2

 #	Article	IF	CITATIONS
37	Rho-kinase Inhibitors: Pharmacomodulations on the Lead Compound Y-32885. Journal of Enzyme Inhibition and Medicinal Chemistry, 2002, 17, 381-390.	2.5	14
38	Synthesis of 5,5′-Dithiobis(2-nitrobenzamides)as Alternative Substrates for Trypanothione Reductase and Thioredoxin Reductase: A Microtiter Colorimetric Assay for Inhibitor Screening. Analytical Biochemistry, 1999, 268, 1-8.	1.1	24